Research Article
Year 2023, Volume: 14 Issue: 3, 353 - 359, 10.07.2023
Abstract
References
- REFERENCES 1. Tangcharoensathien V, Bassett MT, Meng Q, Mills A. Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State. bmj. 2021;372
- 2. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet infectious diseases. 2021;21(2):181-192.
- 3. Malesza M, Wittmann E. Acceptance and intake of COVID-19 vaccines among older Germans. medRxiv. 2021;
- 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021;384(5):403-416.
- 5. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-1993.
- 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383(27):2603-2615.
- 7. Meo S, Bukhari I, Akram J, Meo A, Klonoff D. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European Review for Medical and Pharmacological Sciences. 2021;25(3):1663-1669.
- 8. Li X, Ostropolets A, Makadia R, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv. 2021;
- 9. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annual review of cell and developmental biology. 2017;33:577-599.
- 10. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology. 2015;
- 11. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951-960.
- 12. Klimek L, Novak N, Hamelmann E, et al. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo journal international. 2021;30(2):51-55.
- 13. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021;
- 14. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey. medRxiv. 2021;
Comparison of Adverse Effects of COVID-19 Vaccines Among Elderly: Pfizer/BioNTech Versus CoronaVac
Year 2023, Volume: 14 Issue: 3, 353 - 359, 10.07.2023Abstract
PURPOSE: The SARS-CoV-2 infection has triggered the Covid-19 pandemic with enormous public health and economic consequences. The safety and efficacy of currently available Covid-19 vaccines have been demonstrated in few studies; however, further information on specific high-risk groups like the elderly with co-morbidities is needed. In this cross-sectional study, we aimed to compare the adverse side effects of two different Covid-19 vaccines (RNA-based Pfizer/BioNTech and inactivated CoronaVac) among the elderly with co-morbidities.
MATERIAL AND METHODS: We selected a total of 800 participants 65 years or older who received either one of the vaccines. We collected data on the possible side effects that have been previously attributed to coronavirus vaccination via quantitative telephone interviews.
RESULTS: We found that both CoronaVac and Pfizer/BioNTech were safe in adults over 65 years old, even with co-morbidities. The most common side effects were pain on the injection site and fatigue. Adverse effects, particularly allergic reactions, were higher in Pfizer/BioNTech vaccinated group compared to the CoronaVac group.
CONCLUSION: In conclusion, even with co-morbidities, both vaccines were well-tolerated among the elderly. As this specific group was largely excluded from the previous trials, we believe that this study may have a contributing impact on vaccine acceptance and health policy decision-making.
Keywords
References
- REFERENCES 1. Tangcharoensathien V, Bassett MT, Meng Q, Mills A. Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State. bmj. 2021;372
- 2. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet infectious diseases. 2021;21(2):181-192.
- 3. Malesza M, Wittmann E. Acceptance and intake of COVID-19 vaccines among older Germans. medRxiv. 2021;
- 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021;384(5):403-416.
- 5. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-1993.
- 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383(27):2603-2615.
- 7. Meo S, Bukhari I, Akram J, Meo A, Klonoff D. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European Review for Medical and Pharmacological Sciences. 2021;25(3):1663-1669.
- 8. Li X, Ostropolets A, Makadia R, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv. 2021;
- 9. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annual review of cell and developmental biology. 2017;33:577-599.
- 10. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology. 2015;
- 11. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951-960.
- 12. Klimek L, Novak N, Hamelmann E, et al. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo journal international. 2021;30(2):51-55.
- 13. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021;
- 14. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey. medRxiv. 2021;
Details
| Primary Language | English |
|---|---|
| Subjects | Infectious Diseases |
| Journal Section | Research Article |
| Authors |
|
| Early Pub Date | June 7, 2023 |
| Publication Date | July 10, 2023 |
| Submission Date | February 24, 2022 |
| Acceptance Date | April 14, 2023 |
| Published in Issue | Year 2023Volume: 14 Issue: 3 |
Cite
| EndNote | %0 Acıbadem Üniversitesi Sağlık Bilimleri Dergisi Comparison of Adverse Effects of COVID-19 Vaccines Among Elderly: Pfizer/BioNTech Versus CoronaVac %A Hakan Evren , Emine Ünal Evren , Serap Argun Barış , Figen Gülen İnce , Cenk Soydan , Ömür Çınar Elçi , Füsun Yıldız %T Comparison of Adverse Effects of COVID-19 Vaccines Among Elderly: Pfizer/BioNTech Versus CoronaVac %D 2023 %J Acıbadem Üniversitesi Sağlık Bilimleri Dergisi %P 1309-470X-1309-5994 %V 14 %N 3 %R doi: 10.31067/acusaglik.1076933 %U 10.31067/acusaglik.1076933 |
